WO2016006856A1 - 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법 - Google Patents
퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법 Download PDFInfo
- Publication number
- WO2016006856A1 WO2016006856A1 PCT/KR2015/006678 KR2015006678W WO2016006856A1 WO 2016006856 A1 WO2016006856 A1 WO 2016006856A1 KR 2015006678 W KR2015006678 W KR 2015006678W WO 2016006856 A1 WO2016006856 A1 WO 2016006856A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- gene
- kefa
- quinoline
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
- C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
- C12Y104/03016—L-Aspartate oxidase (1.4.3.16)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02019—Nicotinate-nucleotide diphosphorylase (carboxylating) (2.4.2.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01072—Quinolinate synthase (2.5.1.72)
Definitions
- the present invention relates to a recombinant microorganism producing quinoline acid and a method for producing quinoline acid using the same.
- Quinolinic acid (2,3-pyridine-dicarboxylic acid) is used as a precursor of chemicals used in a wide variety of fields, such as pharmaceuticals, agricultural chemicals, dyeing materials.
- the quinoline acid can be prepared through chemical or biological synthesis methods. Chemically, it is usually prepared by the oxidation of quinoline. Biologically, Escherichia coli strains enhanced expression of two enzymes, L-aspartic acid oxidase (NadB) and quinoline acid synthase (NadA), in E. coli depleted of quinoline phosphoribosyltransferase (NadC) A method for producing quinoline acid using is disclosed.
- KefA is a membrane protein belonging to a mechanosensitive (MS) channel present in microorganisms such as E. coli, and has a function of inducing ions and solutes into cells through a cell membrane.
- KefA in E. coli constitutes the K + efflux system (K + efflux system) with KefB and KefC, particularly KefA the osmotic shock (osmotic down shock) when it is known to play an important role in K + efflux (J. Bacteriol. 169 , 3743-3749, 1987). It has also been reported that the mutation of KefA gene in E. coli is more sensitive to K + concentration and pressure than the wild type (J. membrane Biol. 150, 143-152). However, as mentioned above, most of the studies focus primarily on the association of KefA with the regulation of potassium ions in the cells, and there have been no studies on the association between KefA and the production of quinoline acid.
- the present inventors conducted a study on the association between the active modification of the mechano-channel protein and the high concentration production of quinoline acid, thereby completing a method of producing quinoline acid at high yield.
- One aspect is to provide a recombinant microorganism that produces quinoline acid with reduced or eliminated activity of the protein of SEQ ID NO: 1.
- Another aspect is to provide a method for producing quinoline acid using the microorganism.
- One aspect provides a recombinant microorganism that produces quinoline acid with reduced or eliminated KefA activity.
- KefA is a membrane protein belonging to a mechanosensitive channel, also referred to as "MscK".
- MscK mechanosensitive channel
- the KefA is potassium dependent, and may have activity of introducing ions and solutes into the cells nonspecifically through the cell membrane.
- KefA is one of the potassium efflux proteins, for example, can be controlled by potassium outflow when bacteria are subjected to osmotic shock.
- the KefA may be derived from a microorganism of the genus Escherichia, specifically having an amino acid sequence of SEQ ID NO: 1, and a homologous 80%, specifically, 90% or more amino acid sequence having substantially KefA activity. Can be included without limitation.
- the sequence having such homology is an amino acid sequence having a biological activity substantially the same as or corresponding to that of the protein of SEQ ID NO: 1, even if some sequences have an amino acid sequence deleted, modified, substituted or added, the scope of the present invention is also included in the scope of the present invention. Inclusion is also obvious.
- the kefA gene sequence may include a polynucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1 or more than 80% homology thereto, the polynucleotide encoding the KefA protein is due to the degeneracy of the codon Alternatively, various modifications may be made to the coding region within the scope of not changing the amino acid sequence of the protein expressed from the coding region in consideration of a codon preferred in the organism to express the protein.
- the polynucleotide sequence of kefA can be obtained from published genome sequences of Escherichia coli (GI: 89107872) or from databases such as the American Biotechnology Information Center (NCBI) and the Japanese DNA Data Bank (DDBJ), for example SEQ ID NO: 10 It has a nucleotide sequence of, and may have a nucleotide sequence of 80%, specifically 90% or more homology thereto. However, it is not limited thereto.
- homology refers to the degree of homology to the amino acid sequence or polynucleotide sequence and can be expressed in percentage.
- homologous sequences thereof having the same or similar activity as a given amino acid sequence or polynucleotide sequence are denoted as "% homology”.
- algorithm BLAST by the literature [Karlin and Altschul, Pro. Natl. Acad. Sci. USA, 90, 5873 (1993)] or FASTA by Pearson (Methods Enzymol., 183, 63 (1990)). Based on this algorithm BLAST, a program called BLASTN or BLASTX has been developed (see http://www.ncbi.nlm.nih.gov).
- quinolinic acid as used herein includes quinolinate or a salt thereof.
- the “salt” is a compound made by the anion of the quinoline acid and the cation of the base, and may include, for example, sodium quinoline salt, quinoline potassium salt, quinoline ammonium salt, quinoline calcium salt, quinoline magnesium salt, and the like. Can be.
- the term "recombinant microorganism” may be a naturally or artificially mutated microorganism or a genetically engineered microorganism.
- An exogenous nucleic acid may be introduced into a microorganism produced by genetic engineering, for example, a genetic engineering method, or a sequence or a location of an endogenous gene of the microorganism may be modified.
- the "recombinant microorganism that produces quinoline acid” of the present invention is a microorganism capable of producing and accumulating quinoline acid from a carbon source in a medium, and can produce quinoline acid with higher productivity than before modification by reducing or eliminating KefA activity.
- the recombinant microorganism is not limited as long as it is a microorganism capable of producing and accumulating quinoline acid, but is not limited to the genus Escherichia, Enterbacter, Erwinia, Serratia, and Providen. Microorganisms belonging to the genus Providencia, Corynebacterium, and Brevibacterium.
- the microorganism may be a microorganism belonging to the genus Escherichia. More specifically, the Escherichia genus microorganism may be Escherichia coli, but is not limited thereto.
- the term "removal of activity" of an enzyme or polypeptide means that the protein mentioned in the microorganism is not expressed at all, or has no activity at all.
- the term “reduction of activity” also means that the activity of the mentioned protein is weakened relative to the intrinsic activity.
- intrinsic activity refers to the activity of a microorganism in its natural state, i.e., the protein that the microorganism originally had without undergoing genetic modification.
- the reduction or elimination of KefA activity may include 1) removal or deletion of a gene encoding the KefA protein, 2) modification of an expression control sequence such that expression of the gene is reduced, and 3) chromosome to attenuate the activity of KefA.
- the modification of the gene sequence in the phase or the promoter of the gene can be carried out by a method of replacing the promoter weaker than the intrinsic promoter, or by a combination of one or more of these methods. However, it is not limited thereto.
- the decrease or removal of the KefA activity may be due to the removal or deletion of the gene encoding the KefA membrane protein.
- the "removal or deletion of the gene” is a part or all of the gene, or its promoter, its terminator region, or the like, so that the gene is not expressed, or the amount of expression is reduced or expressed, but does not exhibit enzymatic activity or the activity is reduced. It means that some or all of them are mutated, substituted, deleted or one or more bases are inserted into a gene.
- removal or deletion of the gene can be achieved through genetic manipulation, such as homologous recombination, mutagenesis, molecular evolution. If the cell contains a plurality of the same genes or two or more different polypeptide homologous homologs, one or more genes may be removed or deleted.
- the recombinant microorganism may be further reduced or eliminated the activity of quinolinate phosphoribosyltransferase (NadC).
- quinolinic acid phosphoribosyltransferase as used herein is meant to have the activity of converting quinoline acid to nicotinic acid mononucleotide.
- the production of quinoline acid in cells can be increased by removing or attenuating the gene having the quinoline acid phosphoribosyltransferase activity.
- the quinoline acid phosphoribosyltransferase may be derived from a microorganism of the genus Escherichia, specifically having an amino acid sequence of SEQ ID NO: 29, and having an homology of 80%, specifically 90% or more, substantially as an amino acid sequence.
- the protein having the activity of the quinoline acid phosphoribosyltransferase includes, without limitation, if the amino acid sequence having a biological activity substantially the same as or corresponding to the protein of SEQ ID NO: 29 as this homology sequence, some sequences It is obvious that cases having an amino acid sequence deleted, modified, substituted or added are also included in the scope of the present invention.
- the sequence of the nadC gene encoding the quinoline acid phosphoribosyltransferase may include a polynucleotide sequence encoding the amino acid sequence of SEQ ID NO: 29.
- the nadC gene sequence can be obtained from the genome sequence of Escherichia coli (GI: 89106990) disclosed in the literature or from a database such as NCBI, DDBJ.
- the nadC gene may have a nucleotide sequence of SEQ ID NO: 11 or a base sequence having 80%, specifically 90% or more homology thereof.
- the accumulation of quinoline acid in cells can be increased by reducing or eliminating the activity of the quinoline acid phosphoribosyltransferase.
- the recombinant microorganism may be additionally increased one or more activities selected from the group consisting of L-aspartate oxidase (NadB) and Quinolinate synthase (NadA).
- the accumulation of ⁇ -iminosuccinate, a precursor of quinoline acid in the cell, and the biosynthesis of ⁇ -iminosuccinate to quinoline acid can be increased, thereby increasing the production of quinoline acid.
- aspartic acid oxidase means an enzyme having an activity of oxidizing L-aspartic acid, and may be referred to as 'L-aspartic acid oxidase'.
- the aspartic acid oxidase may be derived from a microorganism of the genus Escherichia. Specifically, the aspartic acid oxidase has an amino acid sequence of SEQ ID NO: 30, and is an amino acid sequence having an homology of 80%, specifically 90% or more. Any protein having an activity is included without limitation, and if it is an amino acid sequence having a biological activity substantially identical to or corresponding to the protein of SEQ ID NO. 30 as the sequence having such homology, some sequences have been deleted, modified, substituted or added. Obviously, it is included in the scope of the present invention.
- the nadB gene encoding the aspartic acid oxidase may include a polynucleotide sequence encoding the amino acid sequence of SEQ ID NO: 30.
- the sequence of the gene nadB can be obtained from the genome sequence of Escherichia coli (GI: 89109380) disclosed in the literature, and from databases such as NCBI and DDBJ.
- the nadB gene may be a nucleotide sequence of SEQ ID NO: 18, or may have a sequence having at least 80% homology thereto, specifically 90% or more. However, it is not limited thereto.
- quinolinic acid synthase refers to an enzyme having the activity of synthesizing quinoline acid from iminosuccinic acid.
- the quinoline synthase may be derived from a microorganism of the genus Escherichia, and specifically has an amino acid sequence of SEQ ID NO: 31, and has an amino acid sequence of at least 80%, specifically 90% or more, substantially quinoline acid synthase.
- Any protein having an activity of an agent is included without limitation. If the sequence having such homology is an amino acid sequence having a biological activity substantially the same as or corresponding to that of the protein of SEQ ID NO: 31, the case where some sequences have an amino acid sequence deleted, modified, substituted or added is also included in the scope of the present invention. Is self-explanatory.
- the nadA gene encoding the quinoline acid synthase may include a polynucleotide sequence encoding the amino acid sequence of SEQ ID NO: 31.
- the sequence of the gene nadA can be obtained from genomic sequences of Escherichia coli (GI: 89107601) published in the literature or from databases such as NCBI and DDBJ.
- the nadA gene encoding the quinoline synthase may be a nucleotide sequence of SEQ ID NO: 21, or may have a sequence having a homology of 80% or more, specifically 90% or more. However, it is not limited thereto.
- the term "increase in activity” means that the activity of the mentioned protein is 'enhanced' relative to the intrinsic activity. Specifically, an increase in the number of copies of the gene encoding the mentioned protein, modification of the expression control sequence to increase the expression of each gene, modification of each said gene sequence on the chromosome to enhance the activity of each protein, promoter of the gene May be performed by a replacement with a stronger promoter than the intrinsic promoter or a combination thereof, but is not limited thereto.
- the increase in the activity of the aspartic acid oxidase or quinoline acid synthase may be by transformation with a recombinant vector comprising a polynucleotide encoding the enzymes.
- transformation refers to introducing a gene into a host cell so that it can be expressed in the host cell.
- Transformed genes are included without limitation, as long as they can be expressed in the host cell, either inserted into the chromosome of the host cell or located outside the chromosome.
- the gene may be introduced in any form as long as it can be expressed by being introduced into a host cell.
- the gene may be introduced into a host cell in the form of an expression cassette, which is a polynucleotide construct containing all the elements necessary for its expression.
- the expression cassette typically includes a promoter, transcription termination signal, ribosomal binding site, and translation termination signal operably linked to the gene.
- the expression cassette may be in the form of an expression vector capable of self replication.
- the gene may be introduced into the host cell in the form of a polynucleotide structure itself or operably linked to a sequence required for expression in the host cell.
- the recombinant vector may be a known expression vector such as a plasmid vector, a cosmid vector, a bacteriophage vector, as a means for expressing a protein by introducing DNA into a host cell.
- the vector can be easily prepared by those skilled in the art according to any known method using DNA recombination technology, but is not limited thereto.
- the increased activity of the enzymes may be by replacing a promoter operably linked to a gene with an enhanced promoter.
- a promoter operably linked to a gene with an enhanced promoter When replacing an nadA and operably linked promoter in embodiments of the present invention in the pCJ1 (Republic of Korea Patent Registration No. 10-0620092) more potent promoter instead pCysK, but confirm that a significant increase quinoline acid production (Table 8) It is not limited to this.
- Another aspect of the present invention comprises the steps of culturing the recombinant microorganism producing the quinoline acid; And recovering quinoline acid from the culture.
- the microorganism producing the quinoline acid is as described above.
- the culture may be made according to the appropriate medium and culture conditions known in the art. Those skilled in the art can easily adjust the medium and culture conditions according to the microorganism selected. Culture methods may include, but are not limited to, batch, continuous, fed-batch, or combination cultures thereof.
- the medium may comprise various carbon sources, nitrogen sources and trace element components.
- the carbon source include glucose, sucrose, lactose, fructose, maltose, starch, carbohydrates such as cellulose, soybean oil, sunflower oil, castor oil, fats such as coconut oil, fatty acids such as palmitic acid, stearic acid, linoleic acid, glycerol and Alcohols such as ethanol, organic acids such as acetic acid, or combinations thereof, and specifically, may be performed using glucose as a carbon source.
- the nitrogen source may be organic nitrogen sources and urea such as peptone, yeast extract, gravy, malt extract, corn steep liquor (CSL), and soybean wheat, inorganic nitrogen sources such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, or Combinations thereof.
- organic nitrogen sources and urea such as peptone, yeast extract, gravy, malt extract, corn steep liquor (CSL), and soybean wheat
- inorganic nitrogen sources such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, or Combinations thereof.
- the medium may comprise, as a source of phosphorus, metal salts such as, for example, potassium dihydrogen phosphate, dipotassium hydrogen phosphate and the corresponding sodium-containing salts, magnesium sulfate or iron sulfate.
- metal salts such as, for example, potassium dihydrogen phosphate, dipotassium hydrogen phosphate and the corresponding sodium-containing salts, magnesium sulfate or iron sulfate.
- amino acids, vitamins, appropriate precursors, and the like may be included in the medium.
- the medium or individual components may be added batchwise or continuously to the culture, the examples are illustrative only and not limited thereto.
- compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid and sulfuric acid can be added to the microbial culture in a suitable manner to adjust the pH of the culture.
- anti-foaming agents such as fatty acid polyglycol esters can be used during the culture to suppress bubble generation.
- oxygen or an oxygen-containing gas eg, air
- the temperature of the culture may be usually 20 °C to 45 °C, for example 25 °C to 40 °C.
- the incubation period can last until the desired amount of quinoline acid is obtained, for example 10 to 160 hours.
- the method for recovering quinoline acid from the culture is to collect or recover the quinoline acid produced from the culture broth using a suitable method known in the art according to a culture method, for example, a batch, continuous or fed-batch culture method. Can be.
- Microorganisms in which the activity of the protein of SEQ ID NO: 1 is reduced or eliminated according to one aspect may be used for quinoline acid production.
- the nadC gene of the quinoline acid degradation pathway was obtained by PCR using the chromosomal DNA of E. coli K12 W3110 as a template. Sequence to obtain: ( "89106990 GI” NCBI registration number), and amplifies the downstream (downstream) part of the nadC gene on the basis of the nadC nucleotide sequence 11 base sequence information of nadC gene from a gene bank (NIH GenBank) of the National Institutes of Health No.
- PCR was performed using the chromosomal DNA of E. coli K12 W3110 as a template and oligonucleotides of SEQ ID NOs: 12, 13, 16, and 17 as primers to amplify the upstream and downstream portions of the nadC gene of 0.5 kb and 0.3 kb, respectively.
- the plasmid vector pLoxpCat2 vector containing the loxpCm (Genbank Accession No.
- oligonucleotides of SEQ ID NOS: 14 and 15 to the nucleotide as a primer to perform PCR nadC gene and homologous sequences in both terminals of the 1.0kb LoxpCm gene was amplified.
- the polymerase was PfuUltra TM DNA polymerase (Stratagene, USA), and PCR was repeated 30 times in a cycle consisting of 30 seconds denaturation at 96 ° C., 30 seconds annealing at 53 ° C., and 1 minute elongation at 72 ° C. Was performed.
- PCR was performed using the nadC -upstream fragment, nadC -downstream fragment, and loxpCm fragment obtained through the PCR reaction as a template, and PCR conditions were 60 seconds of denaturation at 96 ° C., 60 seconds of denaturation at 50 ° C., and 72 10 repetitions of the cycle consisting of 1 minute elongation at ° C. and 20 repetitions of the cycle after addition of the primers of SEQ ID NOs: 12 and 17.
- an nadC deletion cassette containing 1.8 kb of nadC gene upstream- loxpCm -downstream was obtained.
- the produced nadC deletion cassette was transformed by electroporation on Escherichia coli K12 W3110 containing a lambda red recombinase expression vector pKD46, and a LB (Luria-Bertani) plate containing chloramphenicol, a selection marker, Strains on tryptone 10 g / L, yeast extract 5 g / L, NaCl 10 g / L, and agar 1.5%) were incubated overnight at 37 ° C., and strains showing resistance to chloramphenicol were selected.
- PCR was carried out under the same conditions using the primers of SEQ ID NOs: 13 and 16 using the selected strains as templates, and the gene size was 1.6 kb for wild strains and 1.3 for nadC- removing strains on 1.0% agarose gel. Deletion of the nadC gene was confirmed by confirming that it was kb. This was named W3110- ⁇ nadC .
- nadC gene was deleted based on the K12 MG1655 strain in the same manner as above, and named MG1655- ⁇ nadC .
- the nucleotide sequence of the kefA gene of SEQ ID NO: 10 (NCBI accession number "GI :: 89107872") from the National Institutes of Health Gene Bank (NIH GenBank), based on SEQ ID NO: 2 and amplifying a downstream portion of the kefA gene; and A primer of SEQ ID NO: 3, a primer of SEQ ID NOs: 4 and 5 upstream and downstream of kefA and amplification of FRT-KM , and a primer of SEQ ID NOs: 6 and 7, amplifying upstream part were synthesized.
- the chromosomal DNA of Escherichia coli W3110 was used as a template, and PCR was performed using primers of SEQ ID NOs: 2, 3, 6, and 7 to amplify upstream and downstream kefA genes of 0.8 Kb and 0.6 Kb, respectively.
- PCR was performed using primers of SEQ ID NOs: 2, 3, 6, and 7 to amplify upstream and downstream kefA genes of 0.8 Kb and 0.6 Kb, respectively.
- the pKD4 vector containing a FRT-Km as the template oligonucleotide of SEQ ID NO: 4 and 5 and the nucleotide primers to perform the PCR amplification was the FRT-Km gene having the kefA homologous sequences at both terminals of 1.4Kb.
- PfuUltra TM DNA polymerase (Stratagene) was used as a polymerase, and PCR was performed in 30 cycles consisting of 30 seconds of denaturation at 96 ° C, 30 seconds of annealing at 53 ° C, and 2 minutes of elongation at 72 ° C.
- the prepared kefA removal cassette was transformed by electroporation on E. coli W3110- ⁇ NadC containing a lambda red recombinase expression vector pKD46 and plated Luria-Bertani (LB) containing kanamycin, the selection marker. After spreading on a medium (tryptone 10g / L, yeast extract 5g / L, NaCl 10g / L, and agar 1.5%) and incubated overnight at 37 °C, strains showing resistance to kanamycin were selected.
- a medium tryptone 10g / L, yeast extract 5g / L, NaCl 10g / L, and agar 1.5
- PCR was performed under the same conditions using the primers of SEQ ID NOs: 8 and 9 using the selected strain as a direct template, followed by removal of 4.2 kb and kefA- deleting strains for wild strains on 1.0% agarose gel. In the case of confirming that the 1.5kb deletion of the kefA gene was confirmed.
- the resulting strain was named W3110- ⁇ nadC ⁇ kefA .
- MG1655- ⁇ nadC ⁇ kefA was deleted from the MG1655- ⁇ nadC strain by the same method using the prepared kefA removal cassette, which was named MG1655- ⁇ nadC ⁇ kefA .
- the nadB gene encoding wild-type L-aspartic acid oxidase derived from E. coli was cloned into the expression vector.
- the chromosome of E. coli K12 W3110 strain ATCC No 23257 was used.
- the gene sequence was used as the nucleotide sequence of the gene of SEQ ID NO: 18 (NCBI accession number "GI: 89109380") from the National Institutes of Health (NIH GenBank).
- the ORF portion of the nadB gene was amplified and primers of SEQ ID NOs: 19 and 20 having restriction enzyme recognition sites NdeI and BamHI were synthesized.
- PCR was performed using the primers of the oligonucleotides of SEQ ID NOs: 19 and 20 as a template of the chromosomal DNA of E. coli K12 W3110 .
- PfuUltra TM DNA polymerase (Stratagene, USA) was used as a polymerase, and PCR was performed in 30 cycles consisting of 30 seconds denaturation at 96 ° C., 30 seconds annealing at 50 ° C., and 2 minutes elongation at 72 ° C. It was.
- an amplified gene of about 1.9 kb containing the nadB ORF gene and the recognition sites of restriction enzymes NdeI and BamHI was obtained.
- nadB gene obtained through the PCR was recovered through agarose gel elution, and then treated with restriction enzymes NdeI and BamHI. After ligation to the pProLar (CloneTech, USA) vector treated with restriction enzymes NdeI and BamHI, L-aspartic acid oxidase was expressed from the nadB gene linked to the pPro promoter.
- the vector produced by the above method was named pPro-nadB vector.
- nadA encoding quinoline acid synthase was obtained by PCR using chromosomal DNA of E. coli W3110 as a template.
- the nucleotide sequence information of the nadA gene of SEQ ID NO: 21 was utilized from the National Institute of Health Gene Bank (NIH GenBank). Based on this, the ATG portion of the nadA gene and the ORF portion containing TAA were amplified and primers of SEQ ID NOs: 22 and 23 having recognition sites of restriction enzymes ApaI and NotI were synthesized.
- PCR was performed using the chromosomal DNA of Escherichia coli W3110 as a template and the oligonucleotides of SEQ ID NOs: 22 and 23 as primers.
- the polymerase uses PfuUltra TM DNA polymerase (Stratagene, USA), and PCR uses a 30 cycle cycle consisting of 30 seconds denaturation at 96 ° C., 30 seconds annealing at 50 ° C., and 2 minutes elongation at 72 ° C. It was performed repeatedly. As a result, an amplified gene of about 1.0 kb containing the recognition sites of the nadA gene and restriction enzymes ApaI and NotI was obtained.
- the cysK promoter was obtained by PCR using the chromosomal DNA of Escherichia coli W3110 as a template. Obtain sequence information of a promoter located within 0.3 kb upstream of the cysK gene from the National Institutes of Health (NIH GenBank) (SEQ ID NO: 24), based on which the cysK promoter and the amplified nadA gene were conjugated. The primers of SEQ ID NOs: 25 and 26 having the recognition sites of restriction enzymes BamHI and ApaI were synthesized.
- PCR was performed using the chromosomal DNA of Escherichia coli W3110 as a template and the oligonucleotides of SEQ ID NOs: 25 and 26 as primers.
- PfuUltra TM DNA polymerase (Stratagene) was used as the polymerase, and PCR conditions were repeated 30 times with a cycle consisting of 30 seconds denaturation at 96 ° C, 30 seconds annealing at 50 ° C, and 1 minute elongation at 72 ° C.
- an amplified gene of about 0.3 kb containing the cysK promoter and restriction enzymes BamHI and ApaI was obtained.
- nadA gene obtained through the PCR was treated with restriction enzymes ApaI and NotI, and the amplified cysK promoter fragments were treated with ApaI and BamHI.
- Restriction enzyme-treated nadA and cysK promoter fragments were cloned through conjugation to the pPro- nadB vector obtained in 1-2 above treated with restriction enzymes NotI and BamHI to finally regulate expression control by the constitutive promoter pPro promoter.
- a 5.9Kb pPro-nadB_pCysK-nadA cloned with the nadA gene that is regulated by the nadB gene and the cysK gene promoter Vectors were produced.
- the pCJ1 promoter having higher activity at K12 W3110 was used instead of the pCysK promoter.
- the plasmid containing the pCJ1 promoter was obtained by PCR using DNA as a template to obtain the pCJ1 promoter.
- primers of SEQ ID NOs: 27 and 28 having recognition sites of restriction enzymes BamHI and ApaI were synthesized.
- PCR was performed using the chromosomal DNA of Escherichia coli W3110 as a template and the oligonucleotides of SEQ ID NOs: 27 and 28 as primers.
- PfuUltra TM DNA polymerase (Stratagene) was used as the polymerase, and PCR conditions were repeated 30 cycles consisting of 30 seconds denaturation at 96 ° C., 30 seconds annealing at 50 ° C., and 1 minute elongation at 72 ° C. It was.
- pCJ1 An amplified gene of about 0.3 kb containing promoter and restriction enzymes BamHI and ApaI was obtained.
- the nadA gene obtained through the PCR was treated with restriction enzymes ApaI and NotI, and the amplified pCJ1 promoter fragments were treated with ApaI and BamHI.
- NadA treated with the restriction enzyme and The pCJ1 promoter fragment was cloned through conjugation to the pPro-nadB vector obtained in the above 1-2 treated with restriction enzymes NotI and BamHI, and finally to the nadB gene and pCJ1 gene promoter, which are controlled by the constitutive promoter pPro promoter. 5.9Kb of pPro-nadB_pCJ1-nadA cloned with nadA gene regulated by Recombinant vectors were constructed.
- nadB and nadA -enhanced plasmids were introduced into the W3110- ⁇ nadC and MG1655- ⁇ nadC strains, respectively.
- the transduction method was transformed using CaCl 2 method, and plated with LB-Km (yeast extract 10g / L, NaCl 5g / L, tryptone 10g / L, agar 1.5%, kanamycin 50ug / L) in a 37 ° C. incubator. The plate was incubated overnight.
- LB-Km yeast extract 10g / L, NaCl 5g / L, tryptone 10g / L, agar 1.5%, kanamycin 50ug / L
- Quinoline acid in the culture was analyzed by HPLC, and the results are shown in Table 2 below. It shows the quinoline acid production capacity of the strain. As can be seen in Table 2, the difference in quinoline acid production was confirmed according to the degree of expression of the quinoline acid-based strain and nadBA . In particular, when nadA gene expression was enhanced with pCJ1 , whose expression intensity was higher than that of the pCysK promoter, the production of quinoline acid in W3110- ⁇ nadC and MG1655- ⁇ nadC of E. coli K12 wild type was significantly increased.
- the strains W3110- ⁇ nadC ⁇ kefA and MG1655- ⁇ nadC ⁇ kefA prepared in 1-4 were transformed into pPro-nadB_pCJ1-nadA plasmids using CaCl 2 method, respectively.
- Each of the transformed strains was plated in LB-Km (yeast extract 10g / L, NaCl 5g / L, tryptone 10g / L, agar 1.5%, kanamycin 50ug / L) in a 37 ° C. incubator and incubated overnight. . Thereafter, single colonies obtained with kanamycin-resistant colonies were inoculated with 1 platinum in 25 mL of quinoline acid titer (Table 1) and incubated at 33 ° C. at 250 rpm for 24 to 72 hours.
- kefA attenuated plasmid was prepared. Gene sequence was used as the base sequence of the gene of SEQ ID NO: 10 (NCBI accession number "GI :: 89107872") of the National Institutes of Health (NIH GenBank). The kefA initiation codon was mutated from ATG to TTG to amplify the ORF portion of the kefA gene, and the primers of SEQ ID NOs: 32 and 33 with restriction enzymes blunt and BamHI were synthesized. In addition, amplifying the auto promoter region of the kefA gene, and synthesized the primers of SEQ ID NO: 34 and 35 having restriction enzyme recognition site SacI and blunt.
- PCR was performed using chromosomal DNA of E. coli K12 W3110 strain (ATCC No. 23257) as a template and oligonucleotides of SEQ ID NOs: 32 and 33 as primers.
- PfuUltra TM DNA polymerase (Stratagene) was used as a polymerase, and PCR was performed in 30 cycles consisting of 30 seconds denaturation at 96 ° C., 30 seconds annealing at 50 ° C., and 30 seconds elongation at 72 ° C.
- an amplified gene of about 0.15 kb containing a kefA ORF site and a restriction site of restriction enzyme BamHI was obtained.
- PCR was performed using primers using oligonucleotides of SEQ ID NOs: 34 and 35 using K12 W3110 chromosomal DNA as a template.
- PfuUltra TM DNA polymerase (Stratagene) was used as a polymerase, and PCR was performed in 30 cycles consisting of 30 seconds denaturation at 96 ° C., 30 seconds annealing at 50 ° C., and 30 seconds elongation at 72 ° C.
- an amplified pKefA promoter of about 0.15 kb containing the kefA auto promoter site and the recognition site of restriction enzyme SacII was obtained.
- the kefA ORF site and pKefA promoter obtained through the PCR were recovered through agarose gel elution, and then treated with BamHI and SacI restriction enzymes, respectively. It was then ligation to the pSG76C (J. Bacteriol. 179 (13), 4426-4428 (1997), NCBI genebank Y09892) vector treated with restriction enzymes BamHI and SacI.
- the pSG76C_kefA * (ATG-> TTG) vector prepared in (1) was transformed by electroporation on E. coli W3110- ⁇ NadC , and LB (Luria-Bertani) plate medium containing chloramphenicol as a selection marker (tryptone 10g / L, yeast extract 5g / L, NaCl 10g / L, and agar 1.5%) and incubated overnight at 37 ° C, strains showing resistance to chloramphenicol were selected.
- PCR was carried out under the same conditions using the primers of SEQ ID NOs: 33 and 34 using the selected strain as a template, and then a 0.30 kb PCR product was obtained on a 1.0% agarose gel, followed by initiation of kefA through sequencing. Strains with codon substitutions from ATG to TTG were finally selected. This was named W3110-DnadC_kefA * (ATG-> TTG) .
- MG1655- ⁇ nadC was transformed by the same method using the pSG76C_kefA * (ATG-> TTG) vector to confirm the initiation codon substitution of kefA , which was named MG1655- ⁇ nadC_kefA * (ATG-> TTG) .
- the pPro-nadB_pCJ1-nadA plasmid introduction strain to W3110 ⁇ nadC ⁇ kefA, in which the engineered nadC was deleted and nadBA was enhanced, was deposited to the Korea Microorganism Conservation Center (KCCM) on November 07, 2013 under the Budapest Treaty and granted accession number KCCM11470P. received.
- KCCM Korea Microorganism Conservation Center
- a chromosome of E. coli K12 W3110 strain was used as a template to produce a vector capable of overexpressing the kefA gene derived from E. coli, and the gene sequence of the National Bank of Health (NIH GenBank)
- the base sequence of the gene of SEQ ID NO: 10 (NCBI accession number "GI :: 89107872") was utilized.
- the ORF portion of the kefA gene was amplified and primers of SEQ ID NOs: 36 and 37 with restriction enzyme recognition sites EcoRV and HindIII were synthesized.
- PCR was performed using oligonucleotides of SEQ ID NOs: 36 and 37 as primers using the chromosomal DNA of E. coli K12 W3110.
- PfuUltra TM DNA polymerase (Stratagene) was used as a polymerase, and PCR was performed in 30 cycles consisting of 30 seconds denaturation at 96 ° C, 30 seconds annealing at 50 ° C, and 2 minutes elongation at 72 ° C.
- an amplified gene of about 3.3 kb containing the kefA ORF gene and the recognition sites of restriction enzymes EcoRV and HindIII was obtained.
- the kefA gene obtained through the PCR was recovered through agarose gel elution, and then treated with restriction enzymes EcoRV and HindIII. It was then ligation to the pCL1920_pRhtB vector treated with restriction enzymes EcoRV and HindIII. Through this, it was expressed from the kefA gene linked to the pRhtB promoter.
- the vector produced by the above method was named pCL_pRhtB-kefA vector.
- KefA membrane protein is involved in the intake of quinoline acid into the cells.
- the removal of kefA may lower the susceptibility to quinoline acid of the quinoline acid-producing strain, and also increase the production of quinoline acid.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
조성 | 농도(리터당) |
포도당 | 70 g |
황산암모늄 | 17 g |
KH2PO4 | 1.0 g |
MgSO4ㆍ7H2O | 0.5 g |
FeSO4ㆍ7H2O | 5 mg |
MnSO4ㆍ8H2O | 5 mg |
ZnSO4 | 5 mg |
탄산칼슘 | 30 g |
효모 추출물 | 2 g |
메티오닌 | 0.15g |
기반 균주 | 플라스미드 | 퀴놀린산(g/L) |
W3110-△nadC | pPro-nadB_pCysK-nadA | 0.5 |
MG1655-△nadC | 0.3 | |
W3110-△nadC | pPro-nadB_pCJ1-nadA | 3.8 |
MG1655-△nadC | 2.0 |
균주 | 플라스미드 | 퀴놀린산(g/L) |
W3110-ΔnadC | pPro-nadB_pCJ1-nadA | 3.6 |
W3110-ΔnadCΔkefA | 4.2 | |
MG1655-ΔnadC | 2.2 | |
MG1655-ΔnadCΔkefA | 2.7 |
균주 | 플라스미드 | 퀴놀린산(g/L) |
W3110-ΔnadC | pPro-nadB_pCJ1-nadA | 3.5 |
W3110-ΔnadC_kefA*(ATG->TTG) | 4.0 | |
MG1655-ΔnadC | 2.1 | |
MG1655-ΔnadC_kefA*(ATG->TTG) | 2.5 |
기반 균주 | 플라스미드 | 배지조건 | OD600 | 소모당(g/L) | 잔존 퀴놀린산 (g/L) |
W3110-ΔnadC | pPro-nadB_pCJ1-nadA | 0g/L 퀴놀린산 | 9.1 | 10.0 | 0.1 |
MG1655-ΔnadC | 8.3 | 9.0 | 0 | ||
W3110-ΔnadC | 13g/L퀴놀린산 | 4.9 | 6.0 | 11.9 | |
MG1655-ΔnadC | 4.5 | 6.0 | 11.8 |
기반 균주 | 플라스미드 | 배지조건 | OD600 | 소모당(g/L) | 잔존 퀴놀린산(g/L) |
W3110-ΔnadC | pPro-nadB_pCJ1-nadApCL1920 | 0g/L퀴놀린산 | 10.2 | 10.0 | 0.2 |
W3110-ΔnadC | pPro-nadB_pCJ1-nadApCL_PrhtB-kefA | 5.2 | 6.2 | 0 | |
W3110-ΔnadCΔkefA | pPro-nadB_pCJ1-nadApCL1920 | 10.5 | 10.0 | 0.2 | |
W3110-ΔnadC | pPro-nadB_pCJ1-nadApCL1920 | 13g/L퀴놀린산 | 5.0 | 6.2 | 12.0 |
W3110-ΔnadC | pPro-nadB_pCJ1-nadApCL_PrhtB-kefA | 2.1 | 3.2 | 11.5 | |
W3110-ΔnadCΔkefA | pPro-nadB_pCJ1-nadApCL1920 | 8.2 | 8.0 | 12.5 |
Claims (7)
- 서열번호 1의 단백질의 활성이 감소되거나 제거된, 퀴놀린산을 생산하는 에스케리키아속 재조합 미생물.
- 제1항에 있어서, 상기 미생물은 추가적으로 퀴놀린산 포스포라이보실트랜스퍼라아제(quinolinate phophoribosyltransferase)의 활성이 감소되거나 제거된, 퀴놀린산을 생산하는 에스케리키아속 재조합 미생물.
- 제1항 또는 제2항에 있어서, 상기 미생물은 아스파라긴산 산화 효소(L-aspartate oxidase) 및 퀴놀린산 신타아제 (Quinolinate synthase)로 이루어진 그룹에서 선택된 하나 이상의 효소의 활성이 추가로 강화되도록 변이된 것인, 퀴놀린산을 생산하는 에스케리키아속 재조합 미생물.
- 제2항에 있어서, 상기 퀴놀린산 포스포리보실트랜스퍼라아제는 서열번호 29의 아미노산 서열을 가지는 것인, 퀴놀린산을 생산하는 에스케리키아속 재조합 미생물.
- 제3항에 있어서, 상기 아스파라긴산 산화 효소는 서열번호 30의 아미노산 서열을 가지며, 상기 퀴놀린산 신타아제는 서열번호 31의 아미노산 서열을 가지는 것인, 퀴놀린산을 생산하는 에스케리키아속 재조합 미생물.
- 제1항에 있어서, 상기 미생물은 대장균(Escherichia coli)인 것인, 퀴놀린산을 생산하는 에스케리키아속 재조합 미생물.
- 제1항의 재조합 미생물을 배양하는 단계; 및배양물로부터 퀴놀린산을 회수하는 단계를 포함하는, 퀴놀린산을 생산하는 방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/323,429 US10344287B2 (en) | 2014-07-07 | 2015-06-30 | Recombinant microorganism producing quinolinic acid and method for producing quinolinic acid using same |
CN201580037044.4A CN107208041B (zh) | 2014-07-07 | 2015-06-30 | 用于生产喹啉酸的重组微生物和使用其生产喹啉酸的方法 |
EP15818940.7A EP3168293B1 (en) | 2014-07-07 | 2015-06-30 | Recombinant microorganism producing quinolinic acid and method for producing quinolinic acid using same |
JP2017500806A JP6491310B2 (ja) | 2014-07-07 | 2015-06-30 | キノリン酸を生産する組み換え微生物、及びそれを利用したキノリン酸の生産方法 |
PL15818940T PL3168293T3 (pl) | 2014-07-07 | 2015-06-30 | Rekombinowany mikroorganizm wytwarzający kwas chinolinowy i sposób wytwarzania kwasu chinolinowego z jego wykorzystaniem |
BR112017000146-2A BR112017000146A2 (ko) | 2014-07-07 | 2015-06-30 | The recombinant microorganisms and methods of production quinoline acid using it to produce acid-quinoline |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0084625 | 2014-07-07 | ||
KR1020140084625A KR101656363B1 (ko) | 2014-07-07 | 2014-07-07 | 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016006856A1 true WO2016006856A1 (ko) | 2016-01-14 |
Family
ID=55064427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/006678 WO2016006856A1 (ko) | 2014-07-07 | 2015-06-30 | 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10344287B2 (ko) |
EP (1) | EP3168293B1 (ko) |
JP (2) | JP6491310B2 (ko) |
KR (1) | KR101656363B1 (ko) |
CN (1) | CN107208041B (ko) |
BR (1) | BR112017000146A2 (ko) |
PL (1) | PL3168293T3 (ko) |
WO (1) | WO2016006856A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201892060A1 (ru) * | 2016-03-16 | 2019-02-28 | ДСМ АйПи АССЕТС Б.В. | Микробная продукция рибозида никотиновой кислоты |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120082673A (ko) * | 2011-01-14 | 2012-07-24 | 씨제이제일제당 (주) | 니코틴산의 제조 방법 |
KR20130080944A (ko) * | 2012-01-06 | 2013-07-16 | 씨제이제일제당 (주) | 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100620092B1 (ko) | 2004-12-16 | 2006-09-08 | 씨제이 주식회사 | 코리네박테리움 속 세포로부터 유래된 신규한 프로모터서열, 그를 포함하는 발현 카세트 및 벡터, 상기 벡터를포함하는 숙주 세포 및 그를 이용하여 유전자를 발현하는방법 |
KR101634582B1 (ko) * | 2013-07-25 | 2016-06-30 | 씨제이제일제당 주식회사 | 니코틴산 또는 nad에 대한 피드백 조절이 해제된 l-아스파르테이트 옥시다제 변이체 및 이를 이용한 퀴놀리네이트 또는 니코틴산 생산 방법 |
-
2014
- 2014-07-07 KR KR1020140084625A patent/KR101656363B1/ko active IP Right Grant
-
2015
- 2015-06-30 BR BR112017000146-2A patent/BR112017000146A2/ko active IP Right Grant
- 2015-06-30 CN CN201580037044.4A patent/CN107208041B/zh active Active
- 2015-06-30 WO PCT/KR2015/006678 patent/WO2016006856A1/ko active Application Filing
- 2015-06-30 EP EP15818940.7A patent/EP3168293B1/en active Active
- 2015-06-30 PL PL15818940T patent/PL3168293T3/pl unknown
- 2015-06-30 JP JP2017500806A patent/JP6491310B2/ja active Active
- 2015-06-30 US US15/323,429 patent/US10344287B2/en active Active
-
2018
- 2018-10-11 JP JP2018192280A patent/JP6697525B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120082673A (ko) * | 2011-01-14 | 2012-07-24 | 씨제이제일제당 (주) | 니코틴산의 제조 방법 |
KR20130080944A (ko) * | 2012-01-06 | 2013-07-16 | 씨제이제일제당 (주) | 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법 |
Non-Patent Citations (2)
Title |
---|
DEBRA MCLAGGAN ET AL., MOLECULAR MICROBIOLOGY, vol. 43, no. 2, 2002, pages 521 - 536, XP055381956 * |
JERRY LR. ET AL., JOURNAL OF BACTERIOLOGY, vol. 111, no. 1, 1972, pages 98 - 102, XP055113177 * |
Also Published As
Publication number | Publication date |
---|---|
KR101656363B1 (ko) | 2016-09-09 |
PL3168293T3 (pl) | 2020-07-27 |
CN107208041B (zh) | 2021-07-06 |
BR112017000146A2 (ko) | 2018-01-09 |
EP3168293A4 (en) | 2017-11-29 |
JP6697525B2 (ja) | 2020-05-20 |
JP2019030314A (ja) | 2019-02-28 |
JP6491310B2 (ja) | 2019-03-27 |
EP3168293A1 (en) | 2017-05-17 |
US10344287B2 (en) | 2019-07-09 |
US20170159059A1 (en) | 2017-06-08 |
KR20160005554A (ko) | 2016-01-15 |
EP3168293B1 (en) | 2020-01-15 |
JP2017520260A (ja) | 2017-07-27 |
CN107208041A (zh) | 2017-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019160301A1 (ko) | 시트레이트 신타아제의 활성이 약화된 변이형 폴리펩타이드 및 이를 이용한 l-아미노산 생산방법 | |
WO2014142463A1 (ko) | L-발린 생산능이 향상된 균주 및 이를 이용한 l-발린 생산방법 | |
WO2019027267A2 (ko) | Atp 포스포리보실 전이효소 변이체 및 이를 이용한 l-히스티딘 생산방법 | |
WO2018124440A2 (ko) | 신규한 이소프로필말레이트 신타제 변이체 및 이를 이용한 l-류신의 생산 방법 | |
WO2013105827A2 (ko) | 퓨트레신 생산능이 향상된 재조합 미생물 및 이를 이용하여 퓨트레신을 생산하는 방법 | |
WO2013095071A2 (ko) | L-라이신 생산능을 갖는 미생물을 이용하여 l-라이신을 생산하는 방법 | |
WO2019117398A1 (ko) | 5'-이노신산을 생산하는 미생물 및 이를 이용한 5'-이노신산의 생산 방법 | |
WO2015064917A1 (ko) | L-라이신 생산능이 향상된 코리네박테리움 속 미생물 및 이를 이용한 l-라이신 생산방법 | |
WO2019190193A1 (ko) | 글라이신 생산능이 증가된 미생물 및 이를 이용한 발효 조성물 생산 방법 | |
WO2015170907A1 (ko) | L-라이신 생산능이 향상된 미생물 및 이를 이용한 l-라이신 생산방법 | |
WO2017034165A1 (ko) | L-라이신 생산능을 가지는 코리네박테리움 속 미생물 및 이를 이용한 l-라이신 생산방법 | |
WO2021112469A1 (ko) | 신규한 분지쇄 아미노산 아미노트랜스퍼라제 변이체 및 이를 이용한 류신 생산방법 | |
WO2017007159A1 (ko) | L-라이신 생산능을 갖는 미생물 및 이를 이용한 l-라이신 생산 방법 | |
WO2016171392A1 (ko) | 글루코네이트 리프레서 변이체, 이를 포함하는 l-라이신을 생산하는 미생물 및 이를 이용한 l-라이신 생산방법 | |
WO2017034164A1 (ko) | L-라이신 생산능을 가지는 코리네박테리움 속 미생물 및 이를 이용한 l-라이신 생산방법 | |
WO2013103246A2 (ko) | 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법 | |
WO2022231368A1 (ko) | 신규한 글루타메이트 합성 효소 서브 유니트 알파 변이체 및 이를 이용한 l-글루탐산 생산 방법 | |
WO2015122569A1 (ko) | L-쓰레오닌 생산능을 가지는 재조합 에스케리키아 속 미생물 및 이를 이용한 l-쓰레오닌의 생산방법 | |
WO2014126384A1 (ko) | L-쓰레오닌 생산능을 가지는 재조합 에스케리키아 속 미생물 및 이를 이용한 l-쓰레오닌의 생산방법 | |
WO2015012641A1 (en) | L-asparatate oxidase variant and a method for producing quinolinate or nicotinic acid using the same | |
WO2015199406A1 (ko) | L-트립토판 생산능을 갖는 에스케리키아속 미생물 및 이를 이용한 l-트립토판의 제조 방법 | |
WO2014171747A1 (ko) | L-트립토판 생산능을 갖는 미생물 및 이를 이용하여 l-트립토판을 생산하는 방법 | |
WO2018093033A1 (ko) | L-라이신을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-라이신의 생산방법 | |
WO2020067618A1 (ko) | 알파-글루코시다제의 활성이 강화된 l-아미노산을 생산하는 미생물 및 이를 이용한 l-아미노산 생산 방법 | |
WO2016006856A1 (ko) | 퀴놀린산을 생산하는 재조합 미생물 및 이를 이용한 퀴놀린산의 생산 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15818940 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15323429 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2017500806 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015818940 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015818940 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017000146 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112017000146 Country of ref document: BR Free format text: REGULARIZAR O DOCUMENTO DE PROCURACAO, UMA VEZ QUE, BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA, OU SEGUNDO MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR DECLARACAO DE VERACIDADE ASSINADA POR PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO OU NO SEU SUBSTABELECIMENTO. Ref country code: BR Ref legal event code: B01E Ref document number: 112017000146 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01Y Ref document number: 112017000146 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112017000146 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170104 |